BURLINGAME, Calif., July 26, 2018 /PRNewswire-PRWeb/ -- Partnering with Dr. Dale Bredesen,
The Bredesen Protocol is a comprehensive personalized program designed to improve cognition and reverse the cognitive decline of SCI, MCI, and early Alzheimer's disease. Continued research and testing by Dr. Bredesen resulted in the evolution of a prior version of the protocol, called MEND, into the Bredesen Protocol, which has identified new and previously unrecognized causes of Alzheimer's disease.
"Through a direct-to-consumer portal, AHNP is providing simple solutions to affected individuals, their families, and practitioners for highly complex and multilayered health problems. AHNP is combining algorithms based on 30 years of research, data processing, biomarker and genetic testing, and medical software integrations to provide a complete end-to-end experience for the affected person" says Lance Kelly, CTO and Co-Chairman of the Board of AHNP Precision Health.
"Medicine is undergoing a revolution, with larger data sets for complex chronic illnesses such as Alzheimer's, resulting in unprecedented improvements, as we have published. AHNP provides the software and platform to allow millions to obtain a "cognoscopy" easily, a ReCODE report, and prevent cognitive decline. Our goal is to reduce the global burden of dementia," says Dr. Dale Bredesen, Chief Science Officer and Board Member of AHNP Precision Health.
"To us, the ReCODE Report is a major breakthrough for patients and providers. It's an innovative tool that establishes a baseline and roadmap that's essential for assisting in the treatment of cognitive decline. Premier Laboratory Services is excited to be AHNP's diagnostic testing partner. We are dedicated to providing high-quality and affordable laboratory testing that could benefit all," says Lanny Raney, Partner at Premier Laboratory Services.
"This is a momentous day for AHNP. Our country-wide launch of the ReCODE system will allow all of us, who may be concerned about cognitive decline, to assess many of the factors that can be associated with the likelihood of developing the disease. Further, this can be the first step in possibly preventing the disease or treating it in its early stages," says Steve Baumgartner, CEO and Co-Chairman of the Board of AHNP Precision Health.
AHNP Precision Health is a patient engagement company focused on precision health that empowers patients, practitioners, hospitals, universities, and corporations to prevent and reverse behavior-related or exposure-related chronic diseases through advanced medical information, algorithms, and scientifically supported behavior modification. For more information, please visit our website at:
PR Contact: Steve Baumgartner, firstname.lastname@example.org
SOURCE AHNP Precision Health
Subscribe to our Free Newsletters!